Axis Securities has issued a BUY rating for Marksans Pharma with a target price of Rs 362. The brokerage cites strategic European expansion and a robust Rs 1,000 Cr net cash position as primary growth drivers. Investors should monitor the company's progress toward its Rs 4,000 Cr revenue target for FY27.
Axis Securities Assigns BUY Rating to Marksans Pharma
Target Price: Rs 362 | Current Market Price: Rs 330
Reader Takeaway: Marksans aims for Rs 4,000 Cr revenue by FY27 backed by strong European expansion and cash reserves.
What just happened
Axis Securities has initiated coverage on Marksans Pharma with a BUY recommendation. The brokerage has set a 3-6 month target price of Rs 362, offering a potential 10% upside from the current market price of Rs 330. This research update highlights the company's aggressive growth strategy and strong balance sheet.
Why this matters
Marksans Pharma is currently executing a strategic shift toward regulated European markets through acquisitions such as QliniQ B.V. and GmbH. Management has outlined a clear path to generating Rs 1,000 Cr in European revenue over the next 3–5 years. With a global formulation capacity of 26 billion units, the company is positioning itself for sustained top-line growth of 15–20%.
The backstory
The company currently maintains a net cash position exceeding Rs 1,000 Cr. This liquidity acts as a significant buffer and provides management with the flexibility to pursue inorganic growth opportunities without excessive reliance on debt.
Risks to watch
Investors should consider potential delays in regulatory product approvals and the operational risks associated with ramping up new production capacities. Additionally, volatility in raw material and solvent prices remains a structural headwind for the pharmaceutical sector.
Context metrics
Marksans Pharma’s long-term target is to reach Rs 4,000 Cr in total revenue within the next two years. The current scale of operations is supported by a global formulation capacity of 26 billion units per annum.